Promis Neurosciences (NASDAQ:PMN) Stock Rating Lowered by Wall Street Zen

Promis Neurosciences (NASDAQ:PMN – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

Other research analysts have also recently issued research reports about the stock. Roth Capital decreased their price target on shares of Promis Neurosciences to $15.00 and set a “buy” rating on the stock in a report on Monday, November 2nd. Chardan Capital set a $20.00 price objective on Promis Neurosciences and gave the company a “buy” rating in a research note on Monday, July 27th. Guggenheim reissued a “buy” rating and set a $69.00 price objective (up from $35.00) on shares of Promis Neurosciences in a research note on Tuesday, July 28th. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Promis Neurosciences in a research report on Thursday. Finally, Weiss Ratings lowered Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Promis Neurosciences currently has a consensus rating of “Moderate Buy” and an average target price of $30.50.

View Our Latest Stock Analysis on Promis Neurosciences

Promis Neurosciences Trading Down 1.6%

Shares of NASDAQ PMN opened at $3.16 on Friday. The stock has a 50 day moving average of $8.16 and a 200-day moving average of $12.35. The company has a market capitalization of $28.44 million, a P/E ratio of -0.92 and a beta of -0.19. Promis Neurosciences has a 12 month low of $2.78 and a 12 month high of $27.40.

Promis Neurosciences (NASDAQ:PMN – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.39. Analysts predict that Promis Neurosciences will post -4.47 EPS for the current fiscal year.

Insider Activity

In other news, Director Eugene Williams purchased 26,500 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were acquired at an average price of $3.43 per share, with a total value of $90,895.00. Following the acquisition, the director directly owned 40,213 shares in the company, valued at approximately $137,930.59. The trade was a 193.25% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Neil Cashman acquired 10,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was purchased at an average price of $3.86 per share, for a total transaction of $38,600.00. Following the transaction, the insider directly owned 14,532 shares of the company’s stock, valued at approximately $56,093.52. This trade represents a 220.65% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 37,816 shares of company stock valued at $134,746. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Promis Neurosciences

Several large investors have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new position in Promis Neurosciences during the 1st quarter valued at approximately $135,000. ADAR1 Capital Management LLC purchased a new stake in Promis Neurosciences in the 1st quarter worth approximately $1,211,000. Yu Fan purchased a new stake in Promis Neurosciences in the 1st quarter worth approximately $4,188,000. Ally Bridge Group NY LLC grew its position in shares of Promis Neurosciences by 66.1% in the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock worth $5,261,000 after buying an additional 164,880 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of Promis Neurosciences in the 1st quarter worth approximately $16,418,000. 50.13% of the stock is owned by institutional investors.

Promis Neurosciences Company Profile

(Get Free Report)

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody-based treatments for neurodegenerative diseases. Its research focuses on misfolded proteins that may contribute to these conditions. The company’s technology is designed to identify disease-associated forms of proteins while distinguishing them from their normally functioning counterparts. Its lead program, PMN310, is an antibody candidate targeting toxic amyloid-beta oligomers for the potential treatment of Alzheimer’s disease.

Featured Articles

Analyst Recommendations for Promis Neurosciences (NASDAQ:PMN)

Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.